Brief: Santhera Partners Up With Ikris Pharma Network For Distribution Of Agamree In India
Aug 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG SANN.S: ENTERS INTO AGREEMENT WITH IKRIS PHARMA NETWORK FOR THE DISTRIBUTION OF AGAMREE® (VAMOROLONE) IN INDIA AGREEMENT BETWEEN SANTHERA AND IKRIS HAS A 5-YEAR TERM AND SANTHERA WILL RECEIVE A PERCENTAGE OF NET SALES SALES ARE EXPECTED TO BEGIN IN Q4 2025 ON A NAMED PATIENT BASIS Source text: ID:nGNX1jLQgl Further company coverage: SANN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million